Lupus affects women at disproportionately high rates— roughly 9 out of 10 patients are female —and research consistently ...

Private rheumatologist Dr Anandita Santosa in Singapore notes how current AI in healthcare priorities practically leave ...

Over 3.4 million people globally are affected by SLE, and it is one of the leading causes of death in young women in the US ...

Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the Phase 2b JASMINE (NCT04882878) study of adults living with systemic lupus erythematosus (SLE) and the initiation of a ...

The JASMINE trial showed nipocalimab's efficacy in SLE, meeting primary and secondary endpoints, including steroid sparing ...

AstraZeneca announces Saphnelo self-administration phase III TULIP-SC trial demonstrates statistically significant and clinically meaningful reduction in SLE disease activity ...

Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential ...

After experiencing her own personal health improvements through red light therapy, she opened her location in 2021 to help ...

Fresh off of a European approval for a subcutaneous version of Saphnelo, AstraZeneca is doubling down on the benefits of the ...

Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug ...

Lupus is often marked by flares, which is when symptoms are usually more obvious.

Positive full results from the Phase III TULIP-SC trial showed the subcutaneous (SC) administration of Saphnelo (anifrolumab) demonstrated a ...